Experienced in Primary Immunodeficiency (PID)

Dr. Ozlem Goker-Alpan

Pediatrics | General Practice
11212 Waples Mill Rd, Suite 103, 
Fairfax, VA 
Accepting New Patients
Experienced in Primary Immunodeficiency (PID)
11212 Waples Mill Rd, Suite 103, 
Fairfax, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ozlem Goker-Alpan is a primary care provider, a Pediatrics specialist and a General Practice provider in Fairfax, Virginia. Dr. Goker-Alpan is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Gaucher Disease, Fabry Disease, Gaucher Disease Type 1, Gaucher Disease Type 3, and Splenectomy. Dr. Goker-Alpan is currently accepting new patients.

Her clinical research consists of co-authoring 83 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
General Practice
Licenses
Pediatrics in MD
Languages Spoken
English
Spanish
Turkish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

11212 Waples Mill Rd, Suite 103, Fairfax, VA 22030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Biological
Study Drug: ST-920
Study Phase: Phase 1/Phase 2
Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC)
Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drug: Hydroxypropyl-beta-cyclodextrin
Study Phase: Phase 3
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Biological
Study Drug: 4D-310
Study Phase: Phase 1/Phase 2
Gaucher Disease During Infancy and Early Childhood and Experience With Enzyme Replacement Therapy (ERT) Using Velaglucerase Alfa (VPRIV): A Combined Retrospective and Prospective Cohort Study
Gaucher Disease During Infancy and Early Childhood and Experience With Enzyme Replacement Therapy (ERT) Using Velaglucerase Alfa (VPRIV): A Combined Retrospective and Prospective Cohort Study
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Other
A Multicenter, Interventional, Retrospective and Prospective Study of Enzyme Replacement Therapy (VPRIV) Clinical Outcomes and Safety in Gaucher Disease Type 1 Patients Previously Treated With Substrate Reduction Therapy
A Multicenter, Interventional, Retrospective and Prospective Study of Enzyme Replacement Therapy (VPRIV) Clinical Outcomes and Safety in Gaucher Disease Type 1 Patients Previously Treated With Substrate Reduction Therapy
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Other
Study Drug: Velaglucerase Alfa
Study Phase: Phase 4
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
Enrollment Status: Completed
Publish Date: February 01, 2022
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 4
An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy
An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease
A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 3
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol
Enrollment Status: Completed
Publish Date: May 28, 2021
An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.
An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.
Enrollment Status: No_longer_available
Publish Date: May 24, 2021
Intervention Type: Biological
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

83 Total Publications

Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience.
Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience.
Journal: Frontiers in pediatrics
Published: April 17, 2025
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. David Heydt
General Practice
Advanced in Primary Immunodeficiency (PID)
Dr. David Heydt
General Practice

Capital Digestive Care LLC

4831 Telsa Dr F, 
Bowie, MD 
 (33.2 miles away)
240-737-0080
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Heydt is a primary care provider, practicing in General Practice in Bowie, Maryland. Dr. Heydt is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Diarrhea, Trichohepatoenteric Syndrome, Gastroesophageal Reflux Disease (GERD), and Gastric Dysmotility. Dr. Heydt is currently accepting new patients.

Shaun Shayegan
Experienced in Primary Immunodeficiency (PID)
Dr. Shaun Shayegan
Allergy and Immunology | Pediatrics
Experienced in Primary Immunodeficiency (PID)
Dr. Shaun Shayegan
Allergy and Immunology | Pediatrics

Office

14520 Avion Pkwy Ste 150, 
Chantilly, VA 
 (6.5 miles away)
703-378-5155
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shaun Shayegan is an Allergy and Immunologist and a Pediatrics provider in Chantilly, Virginia. Dr. Shayegan is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Allergic Rhinitis, Sinusitis, Hives, and Grass Allergy.

Experienced in Primary Immunodeficiency (PID)
Dr. Shelby Josephs
Pediatrics
Experienced in Primary Immunodeficiency (PID)
Dr. Shelby Josephs
Pediatrics

Scanlon And Josephs M.D. P.A.

6000 Executive Blvd Ste 615, 
Rockville, MD 
 (17.6 miles away)
301-530-7907
Languages Spoken:
English
See accepted insurances

Shelby Josephs is a Pediatrics provider in Rockville, Maryland. Dr. Josephs is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Allergic Rhinitis, Sinusitis, Grass Allergy, and Angioedema.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goker-Alpan's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile